PLUS THERAPEUTICS, INC.

Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.

PSTV | US

Overview

Corporate Details

ISIN(s):: US23283K2042 (+1 more)
LEI:
Country:: United States of America
Address:: 4200 MARATHON BLVD., 78756 AUSTIN
Website:: http://www.plustherapeutics.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company's proprietary platform is designed to deliver a single, high-dose of radiation directly to tumors while minimizing damage to healthy tissue. This is achieved by encapsulating Rhenium radioisotopes within novel delivery systems like nanoliposomes and biodegradable microspheres. Its lead drug candidate, REYOBIQ™ (rhenium Re186 obisbemeda), targets central nervous system (CNS) cancers, including glioblastoma and leptomeningeal metastases. The company's pipeline also includes a next-generation therapy for solid organ cancers, such as liver cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PLUS THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PLUS THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for PLUS THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Kolon TissueGene, Inc. Developing cell and gene therapies for orthopedic and degenerative disorders.	United States of America	950160
KOMIPHARM INTERNATIONAL CO., LTD. Develops animal health products and novel drugs for human cancer and autoimmune diseases.	South Korea	041960
KOREA ARLICO PHARM CO.,LTD. Manufactures generic drugs and provides CDMO services to a global market.	South Korea	260660
KOREAN DRUG CO., LTD. Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.	South Korea	014570
Korro Bio, Inc. A clinical-stage biopharma using RNA editing to develop medicines for rare & prevalent diseases.	United States of America	KRRO
K Pharma,Inc. Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.	Japan	4896
Kringle Pharma,Inc. Develops regenerative HGF medicines for rare and intractable neurological diseases.	Japan	4884
Krka Develops and sells generic prescription, non-prescription, and animal health products globally.	Slovenia	KRKG
Krystal Biotech, Inc. Developing redosable gene therapies for rare diseases using a modified HSV-1 vector.	United States of America	KRYS
KUKJEON PHARMACEUTICAL Co.,Ltd A chemical solutions provider manufacturing Active Pharmaceutical Ingredients and electronic materials.	South Korea	307750